Table 1.

Inactivated vaccines against COVID-19 approved for use.

Name	Producer	Schedule	Efficacy	Pre-clinical ref	Clinical ref
BBIBP-CorV	Beijing Institute of Biological Products + Sinopharm, China	2 doses, 3 weeks apart	78.1%	27	26
–	Wuhan Institute of Biological Products + Sinopharm, China	2–3 doses, 3–4 weeks apart	72.8%	–	27
CoronaVac (formerly PiCoVacc)	Sinovac Biotech, China	2 doses, 2 weeks apart	50.65–83.5%	25	20
Covaxin (also known as BBV152 A, B, C)	Indian Council of Medical Research + the National Institute of Virology + Bharat Biotech	2 doses, 4 weeks apart	77.8%	24	18